Establishment of a Study Group on Clinical Laboratory Reagent Wholesale Business by Alfresa Corporation and Seiko Corporation
Alfresa and Seiko have established a joint study group to optimize and advance the supply chain for clinical laboratory reagents, aiming to address rising demand and logistics costs.
📋 Article Processing Timeline
- 📰 Published: June 1, 2026 at 15:00
- 🔍 Collected: June 1, 2026 at 15:27 (27 min after Published)
- 🤖 AI Analyzed: June 1, 2026 at 18:04 (2h 37m after Collected)
Alfresa Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Yusuke Fukujin), a subsidiary of our company, has decided to establish a study group with Seiko Corporation (Headquarters: Fukuoka City, Fukuoka Prefecture; President: Masatoshi In) to focus on the efficiency and advancement of the supply chain in the clinical laboratory reagent wholesale business. In the clinical laboratory reagent industry, testing is becoming more sophisticated and diverse due to the aging population and the progress of personalized medicine. Additionally, changes in the external environment, such as rising raw material and logistics costs, have increased the importance of stable supply. Alfresa leverages a nationwide distribution network, while Seiko has a strong foundation as a specialized trading company for clinical laboratory reagents, primarily in Kyushu and Okinawa. By combining their expertise, both companies aim to develop solutions for industry-wide challenges.
FAQ
Does this partnership affect the Taiwanese medical industry?
There is no direct impact, but Japan's logistics efficiency models may serve as a reference for Taiwan's medical supply chain management.